Exclusion Criteria
concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms
boolean
The patient has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease
boolean
prior therapy with mitoxantrone for advanced prostate cancer
boolean
The patient has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is >= 10% below the lower limit of normal institutional range
boolean
history of prior treatment with other agents that directly inhibit PDGF or platelet-derived growth factor receptors
boolean
known allergy to any of the treatment components: IMC 3G3, mitoxantrone, and/or prednisone
boolean
radiotherapy within 21 days prior to first dose of IMC-3G3
boolean
any investigational therapy within 30 days of randomization
boolean
is receiving corticosteroids at a dose > 5 mg prednisone orally (PO) 2 times per day (BID) or equivalent
boolean
received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain
boolean
has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders
boolean
known or suspected brain or leptomeningeal metastases
boolean
known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
boolean